Angiotensin Type 1 Receptor Activation Promotes Neuronal and Glial Alpha-synuclein Aggregation and Transmission

Overview

Journal NPJ Parkinsons Dis

Date 2024 Feb 17

PMID 38368444

Authors

Lucia Lage

Ana I Rodriguez-Perez

Begona Villar-Cheda

Jose L Labandeira-Garcia

Antonio Dominguez-Meijide

Affiliations

Soon will be listed here.

Abstract

The brain renin-angiotensin system (RAS) has been related to dopaminergic degeneration, and high expression of the angiotensin II (AngII) type 1 receptor (AT1) gene is a marker of the most vulnerable neurons in humans. However, it is unknown whether AngII/AT1 overactivation affects α-synuclein aggregation and transmission. In vitro, AngII/AT1 activation increased α-synuclein aggregation in dopaminergic neurons and microglial cells, which was related to AngII-induced NADPH-oxidase activation and intracellular calcium raising. In mice, AngII/AT1 activation was involved in MPTP-induced increase in α-synuclein expression and aggregation, as they significantly decreased in mice treated with the AT1 blocker telmisartan and AT1 knockout mice. Cell co-cultures (transwells) revealed strong transmission of α-synuclein from dopaminergic neurons to astrocytes and microglia. AngII induced a higher α-synuclein uptake by microglial cells and an increase in the transfer of α-synuclein among astroglial cells. However, AngII did not increase the release of α-synuclein by neurons. The results further support brain RAS dysregulation as a major mechanism for the progression of Parkinson's disease, and AT1 inhibition and RAS modulation as therapeutic targets.

Citing Articles

Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons.

Rivas-Santisteban R, Munoz A, Lillo J, Raich I, Rodriguez-Perez A, Navarro G NPJ Parkinsons Dis. 2024; 10(1):220.

PMID: 39548112 PMC: 11568119. DOI: 10.1038/s41531-024-00827-7.

Insights into Calpain Activation and Rho-ROCK Signaling in Parkinson's Disease and Aging.

Gathings A, Zaman V, Banik N, Haque A Biomedicines. 2024; 12(5).

PMID: 38791036 PMC: 11117523. DOI: 10.3390/biomedicines12051074.

The role of the brain renin-angiotensin system in Parkinson´s disease.

Labandeira-Garcia J, Labandeira C, Guerra M, Rodriguez-Perez A Transl Neurodegener. 2024; 13(1):22.

PMID: 38622720 PMC: 11017622. DOI: 10.1186/s40035-024-00410-3.

References

Outeiro T . Alpha-synuclein oligomerization and aggregation: A model will always be a model: This is a response to.... J Neurochem. 2020; 157(4):889-890. DOI: 10.1111/jnc.15264. View

Garrido-Gil P, Rodriguez-Perez A, Fernandez-Rodriguez P, Lanciego J, Labandeira-Garcia J . Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells. Brain Struct Funct. 2017; 222(6):2559-2571. DOI: 10.1007/s00429-016-1357-z. View

Dominguez-Meijide A, Parrales V, Vasili E, Gonzalez-Lizarraga F, Konig A, Lazaro D . Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo. Neurobiol Dis. 2021; 151:105256. DOI: 10.1016/j.nbd.2021.105256. View

Gao H, Liu B, Zhang W, Hong J . Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 2003; 17(13):1954-6. DOI: 10.1096/fj.03-0109fje. View

Labandeira-Garcia J, Valenzuela R, Costa-Besada M, Villar-Cheda B, Rodriguez-Perez A . The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons. Prog Neurobiol. 2020; 199:101919. PMC: 7543790. DOI: 10.1016/j.pneurobio.2020.101919. View

Izumisawa Y, Tanaka-Yamamoto K, Ciriello J, Kitamura N, Shibuya I . Persistent cytosolic Ca increase induced by angiotensin II at nanomolar concentrations in acutely dissociated subfornical organ (SFO) neurons of rats. Brain Res. 2019; 1718:137-147. DOI: 10.1016/j.brainres.2019.05.014. View

Koeglsperger T, Rumpf S, Schliesser P, Struebing F, Brendel M, Levin J . Neuropathology of incidental Lewy body & prodromal Parkinson's disease. Mol Neurodegener. 2023; 18(1):32. PMC: 10182593. DOI: 10.1186/s13024-023-00622-7. View

Kim C, Ho D, Suk J, You S, Michael S, Kang J . Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013; 4:1562. PMC: 4089961. DOI: 10.1038/ncomms2534. View

Yang Y, Qin M, Bao P, Xu W, Xu J . Secretory carrier membrane protein 5 is an autophagy inhibitor that promotes the secretion of α-synuclein via exosome. PLoS One. 2017; 12(7):e0180892. PMC: 5507457. DOI: 10.1371/journal.pone.0180892. View

10.

Joglar B, Rodriguez-Pallares J, Rodriguez-Perez A, Rey P, Guerra M, Labandeira-Garcia J . The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem. 2009; 109(2):656-69. DOI: 10.1111/j.1471-4159.2009.05999.x. View

11.

Stolk J, Hiltermann T, Dijkman J, Verhoeven A . Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol. 1994; 11(1):95-102. DOI: 10.1165/ajrcmb.11.1.8018341. View

12.

Engelender S, Kaminsky Z, Guo X, Sharp A, Amaravi R, Kleiderlein J . Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet. 1999; 22(1):110-4. DOI: 10.1038/8820. View

13.

Kowall N, Hantraye P, Brouillet E, Beal M, McKee A, Ferrante R . MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 2000; 11(1):211-3. DOI: 10.1097/00001756-200001170-00041. View

14.

Drozdova P, Barbitoff Y, Belousov M, Skitchenko R, Rogoza T, Leclercq J . Estimation of amyloid aggregate sizes with semi-denaturing detergent agarose gel electrophoresis and its limitations. Prion. 2020; 14(1):118-128. PMC: 7199750. DOI: 10.1080/19336896.2020.1751574. View

15.

Trinkaus V, Riera-Tur I, Martinez-Sanchez A, Bauerlein F, Guo Q, Arzberger T . In situ architecture of neuronal α-Synuclein inclusions. Nat Commun. 2021; 12(1):2110. PMC: 8046968. DOI: 10.1038/s41467-021-22108-0. View

16.

Chen K, Menezes K, Rodgers J, OHara D, Tran N, Fujisawa K . Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Mol Neurodegener. 2021; 16(1):77. PMC: 8588601. DOI: 10.1186/s13024-021-00497-6. View

17.

Hettiarachchi N, Parker A, Dallas M, Pennington K, Hung C, Pearson H . alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem. 2009; 111(5):1192-201. DOI: 10.1111/j.1471-4159.2009.06411.x. View

18.

Labandeira-Garcia J, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B, Rodriguez-Perez A . Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov Disord. 2013; 28(10):1337-42. DOI: 10.1002/mds.25614. View

19.

Zampese E, Surmeier D . Calcium, Bioenergetics, and Parkinson's Disease. Cells. 2020; 9(9). PMC: 7564460. DOI: 10.3390/cells9092045. View

20.

Rodriguez-Pallares J, Rey P, Parga J, Munoz A, Guerra M, Labandeira-Garcia J . Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis. 2008; 31(1):58-73. DOI: 10.1016/j.nbd.2008.03.003. View